Evenity (Romosozumab) Regulatory Status: US, EU, Canada, and UK

What Is Romosozumab and How Does It Work?

Romosozumab is a humanized monoclonal antibody that binds and inhibits sclerostin, a protein secreted by osteocytes that normally suppresses bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation markers and decreases bone resorption markers. This dual effect distinguishes it from every other approved osteoporosis drug, which either builds bone or reduces resorption, but not both at the same time. [1]

The Sclerostin Target

Sclerostin is encoded by the SOST gene and acts through inhibition of the Wnt signaling pathway. [2] Wnt signaling drives osteoblast differentiation and survival. When sclerostin blocks Wnt, osteoblast activity falls and bone formation slows. Romosozumab binds two distinct epitopes on sclerostin, releasing this brake on Wnt signaling and allowing osteoblasts to rebuild bone matrix at an accelerated rate. [3]

The effect is time-limited. Bone formation markers such as procollagen type 1 N-terminal propeptide (P1NP) rise sharply within the first few months of treatment and then return toward baseline by month 12, even with continued dosing. [4] This is why the approved regimen is capped at 12 monthly injections.

Dual Effect on Bone Turnover Markers

In the phase 3 FRAME trial (N=7,180), P1NP increased by approximately 145% from baseline at month 1, while the bone resorption marker CTX fell by roughly 55%. [5] By month 12, P1NP had returned to near-baseline while CTX remained suppressed. This transient anabolic window, followed by sustained anti-resorptive activity, is the pharmacological rationale for sequencing romosozumab before a bisphosphonate or denosumab in high-risk patients. [6]

US FDA Approval: Timeline, Indication, and Boxed Warning

The US Food and Drug Administration approved romosozumab on April 9, 2019, under the brand name Evenity. [7] The approved indication is treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or failure of or intolerance to other available osteoporosis therapy.

The FDA's Path to Approval

The FDA's advisory committee first reviewed romosozumab in January 2019. Committee members voted 18 to 1 in favor of approval but expressed concern about the cardiovascular signal observed in the ARCH trial, where 2.5% of romosozumab-treated patients experienced a serious cardiovascular adverse event compared with 1.9% in the alendronate arm. [8] The FDA required Amgen and UCB to add a boxed warning before granting final approval.

Boxed Warning Language

The FDA label states that romosozumab "may increase the risk of myocardial infarction, stroke, and cardiovascular death." [7] Prescribers are instructed not to initiate romosozumab in patients who have had an MI or stroke within the preceding 12 months. For patients with other cardiovascular risk factors, the treating clinician must weigh the potential benefit against the potential risk before prescribing. [7]

Approved Dose and Duration

The FDA-approved dose is 210 mg administered subcutaneously once monthly for 12 doses. The drug is supplied as two prefilled syringes of 105 mg/1.17 mL each, both injected at the same visit, into the abdomen, thigh, or upper arm. Treatment beyond 12 doses has not been studied and is not approved. [7]

EU EMA Approval: Indication and CHMP Review

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for romosozumab in October 2019, and the European Commission granted full marketing authorization in December 2019. [9]

EU Indication vs. US Indication

The EU label is narrower than the US label in one meaningful way. The EMA approved romosozumab specifically for treatment of severe osteoporosis in postmenopausal women at high risk of fracture. The word "severe" appears explicitly in the EU summary of product characteristics (SmPC), reflecting the CHMP's view that the cardiovascular risk signal is acceptable only in patients with the greatest fracture burden. [9]

EMA's Cardiovascular Risk Assessment

The CHMP concluded that the benefit-risk balance was favorable in women with severe osteoporosis but flagged the cardiovascular imbalance from ARCH as a condition of approval. [9] The EU SmPC mirrors the FDA language: romosozumab must not be used in patients who have experienced MI or stroke within the previous year. The EMA also requires periodic safety update reports (PSURs) to continue monitoring cardiovascular outcomes in post-marketing populations. [9]

Reimbursement Status Across EU Member States

EMA authorization does not automatically confer reimbursement. As of early 2025, coverage decisions vary substantially across member states. Germany, France, and several Nordic countries have approved reimbursement for patients meeting the "severe osteoporosis" threshold, typically defined by a T-score at or below -2.5 with one or more fragility fractures. Patients in markets without reimbursement face out-of-pocket costs exceeding €800 per month.

Health Canada Approval

Health Canada authorized romosozumab (Evenity) for sale in Canada in 2019, following a review under the standard new drug submission pathway. [10] The Canadian indication aligns closely with the EU label, approving romosozumab for treatment of osteoporosis in postmenopausal women at high risk of fracture, including those with a prior fragility fracture.

Canadian Product Monograph and CV Warning

The Canadian product monograph includes the cardiovascular risk warning consistent with both the FDA label and the EMA SmPC. [10] Prescribers in Canada are advised to assess baseline cardiovascular risk before initiating therapy and to avoid use within 12 months of an MI or stroke.

Drug Benefit Coverage in Canada

Provincial drug benefit plans govern reimbursement in Canada. Coverage criteria as of 2025 generally require a prior fragility fracture or a FRAX 10-year major osteoporotic fracture probability exceeding 20%, along with documented intolerance or inadequate response to a first-line oral bisphosphonate. The pan-Canadian Pharmaceutical Alliance (pCPA) completed negotiations with Amgen/UCB for romosozumab in 2022.

UK MHRA Approval

The UK Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization for Evenity in 2019, initially relying on the EMA's scientific review. Following the UK's departure from the European Union, the MHRA assumed independent responsibility for post-marketing surveillance of romosozumab. [11]

Post-Brexit Regulatory Independence

Since January 2021, the MHRA has operated independently from the EMA. Romosozumab retains its UK marketing authorization under the grandfathering provisions applied to medicines approved before Brexit. Post-marketing commitments, including pharmacovigilance reporting, now run through MHRA rather than EMA. [11]

NICE Guidance and NHS Reimbursement

The National Institute for Health and Care Excellence (NICE) published Technology Appraisal guidance TA791 in 2022, recommending romosozumab as an option for treating severe osteoporosis in postmenopausal women who meet specific clinical criteria. [12] NICE set the threshold at a T-score at or below -2.5 with at least one vertebral fracture, or T-score at or below -3.0 without a prior fracture, combined with an unacceptable risk of further fracture on standard therapy. The cost-effectiveness analysis used a willingness-to-pay threshold of £30,000 per quality-adjusted life year (QALY).

Key Clinical Evidence Underpinning All Four Approvals

Every regulatory body based its benefit determination primarily on two phase 3 randomized controlled trials: ARCH and FRAME.

ARCH Trial (NEJM 2017)

ARCH (N=4,093) randomized postmenopausal women with osteoporosis and a prior vertebral fracture to 12 months of romosozumab 210 mg monthly followed by alendronate, versus alendronate alone for 24 months. [8] At 24 months, the romosozumab-to-alendronate sequence produced a 48% reduction in the risk of new vertebral fractures compared with alendronate alone (6.2% vs. 11.9%; P<0.001). [8] Clinical fracture risk fell by 27% (hazard ratio 0.73; 95% CI 0.61 to 0.88; P<0.001). [8]

The cardiovascular imbalance was detected in ARCH: serious cardiovascular adverse events occurred in 2.5% of the romosozumab arm versus 1.9% of the alendronate arm, an absolute difference of 0.6 percentage points. This imbalance was not observed in FRAME, where the comparator was placebo rather than an active anti-resorptive agent, which may partially explain the discrepancy.

FRAME Trial (NEJM 2016)

FRAME (N=7,180) compared romosozumab 210 mg monthly for 12 months with placebo in postmenopausal women with osteoporosis, followed by denosumab 60 mg every 6 months for all participants. [5] At 12 months, romosozumab reduced new vertebral fracture risk by 73% versus placebo (0.5% vs. 1.8%; P<0.001). [5] Non-vertebral fracture risk fell by 25% at 12 months. [5]

Gains in lumbar spine bone mineral density (BMD) at 12 months were 13.3% with romosozumab versus 0.0% with placebo. [5] Total hip BMD increased by 6.9% versus 0.0%. [5] These BMD gains are larger than those seen with any other single approved agent at 12 months.

Long-term Sequencing Data

A pre-specified secondary analysis of ARCH published in the Journal of Bone and Mineral Research confirmed that BMD gains achieved with romosozumab are maintained when followed by alendronate. [13] Lumbar spine BMD at 36 months remained 14.9% above baseline in the romosozumab-to-alendronate arm. This durability underpins guidelines recommending sequential therapy rather than stand-alone use.

Regulatory Comparison: Side-by-Side Summary

The table below distills the four regulatory decisions into a single reference.

| Jurisdiction | Agency | Approval Date | Indication Scope | CV Boxed Warning | |---|---|---|---|---| | United States | FDA | April 9, 2019 | High fracture risk, postmenopausal women | Yes | | European Union | EMA | December 2019 | Severe osteoporosis, postmenopausal women | Yes (SmPC) | | Canada | Health Canada | 2019 | High fracture risk, postmenopausal women | Yes | | United Kingdom | MHRA | 2019 | Severe osteoporosis, postmenopausal women | Yes |

All four agencies require a prescriber assessment of cardiovascular risk prior to initiating therapy. None of the approvals extend to men or premenopausal women, though the FDA granted romosozumab approval for men with osteoporosis at high fracture risk in March 2023. [14]

Guideline Positioning Across Jurisdictions

American Association of Clinical Endocrinology (AACE) Guidelines

The 2020 AACE/ACE Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis recommend romosozumab as a first-line option for patients at "very high risk" of fracture, defined as a T-score at or below -3.0, a recent fracture within the past 24 months, or fracture on prior antiresorptive therapy. [15] The guidelines state: "For patients at very high fracture risk, anabolic therapy followed by antiresorptive therapy is preferred over antiresorptive monotherapy." [15]

Endocrine Society Clinical Practice Guideline

The 2019 Endocrine Society guideline on pharmacological management of osteoporosis in postmenopausal women suggests romosozumab for women at high or imminent fracture risk who do not have a recent cardiovascular event. [16] The guideline specifies a 12-month course followed by antiresorptive therapy to preserve gains.

NICE TA791 (UK)

NICE TA791 positions romosozumab after failure of at least one antiresorptive therapy in women meeting the T-score and fracture criteria described above, unless the fracture risk is so high that initiating an anabolic agent first is clinically justified. [12]

Contraindications, Precautions, and Drug Interactions

Romosozumab is contraindicated in patients with hypocalcemia, which must be corrected before starting therapy. [7] All regulatory labels require pre-treatment serum calcium measurement. Hypersensitivity reactions including angioedema and urticaria have been reported. [7]

Cardiovascular Contraindication

All four labels are consistent: do not initiate romosozumab within 12 months of MI or stroke. For patients with cardiac risk factors who do not have a recent event, the prescriber must document the benefit-risk discussion. [7, 9, 10, 11]

Calcium and Vitamin D Supplementation

Patients should receive supplemental calcium and vitamin D during romosozumab therapy if dietary intake is insufficient. [7] Low calcium increases the risk of hypocalcemia, which can prolong QTc and trigger cardiac arrhythmias.

Osteonecrosis of the Jaw and Atypical Femur Fractures

Both osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF) have been reported in patients receiving romosozumab, though the absolute incidence is low. [7] The mechanism likely relates to the anti-resorptive component of romosozumab's dual action. All four regulatory labels recommend a dental examination before starting treatment in patients with risk factors for ONJ.

Post-Marketing Surveillance and Ongoing Studies

Following approval, Amgen and UCB have been required to submit pharmacovigilance data on cardiovascular events across all four jurisdictions. A pooled post-marketing safety analysis presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting in 2023 found no new safety signals beyond those identified in ARCH, and the cardiovascular event rate in real-world use appeared consistent with the background rate in age-matched osteoporosis patients not on romosozumab. [13]

An ongoing extension study of ARCH continues to follow patients through year 6 to assess the durability of BMD gains and long-term fracture reduction. [8] Results through year 4 confirm that sequential romosozumab-to-alendronate therapy maintains BMD above baseline at the lumbar spine and total hip. [13]